Treatment advances for overactive bladder 'pushing the therapeutic index'
Chicago-Some researchers investigating the physiology and treatment ofoveractive bladder have questioned whether a "therapeutic ceiling"has been reached with anticholinergic medications, the current mainstayof treatment. Although the balance between efficacy and tolerability ofanticholinergics falls short of ideal, a number of products under developmenthold promise, said Roger Dmochowski, MD, professor of urology at VanderbiltUniversity School of Medicine in Nashville, TN.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.